KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abbott Laboratories (ABT) Accumulated Expenses (2016 - 2025)

Abbott Laboratories (ABT) has disclosed Accumulated Expenses for 17 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • Quarterly Accumulated Expenses rose 2.59% to $1.7 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 billion through Dec 2025, up 2.59% year-over-year, with the annual reading at $1.7 billion for FY2025, 2.59% up from the prior year.
  • Accumulated Expenses hit $1.7 billion in Q4 2025 for Abbott Laboratories, up from $1.7 billion in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $1.7 billion in Q4 2025 to a low of $1.1 billion in Q1 2024.
  • Historically, Accumulated Expenses has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2021.
  • Biggest five-year swings in Accumulated Expenses: increased 17.7% in 2021 and later fell 4.27% in 2023.
  • Year by year, Accumulated Expenses stood at $1.6 billion in 2021, then fell by 4.25% to $1.6 billion in 2022, then grew by 2.63% to $1.6 billion in 2023, then grew by 6.51% to $1.7 billion in 2024, then grew by 2.59% to $1.7 billion in 2025.
  • Business Quant data shows Accumulated Expenses for ABT at $1.7 billion in Q4 2025, $1.7 billion in Q3 2025, and $1.6 billion in Q2 2025.